OSLO, Norway, Aug. 25, 2016 — Targovax ASA , a clinical stage immuno-oncology company developing targeted immunotherapy treatments for cancer patients, announces its second quarter and first half year 2016 results. A meeting for investors, analysts and press will take place in Oslo today at 10:00 CET and a conference call will take place at 14.00 CET .
